A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggested big pharma may finally be willing to place ...

The 17 advisers fired last month by Robert F. Kennedy Jr. urged alternatives to ACIP be organized to limit further ...

The White House set a 60-day deadline for drugmakers to agree on “most favored nation” prices for Medicaid as well as for ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...